Henry Ford Health

Running trials

• Not yet recruiting

  Symptom Management to Improve Completion of Patient-reported Outcome Measures

  NCT07723495· Henry Ford Health System· Source

• Not yet recruiting

  Safety Study of XT-150 in Participants With ALS

  NCT06704347· Phase 1· Xalud Therapeutics, Inc.· Source

• Not yet recruiting

  An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

  NCT07923526· Phase 2/3· United Therapeutics· Source

• Not yet recruiting

  Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

  NCT07450183· Phase 2· Henry Ford Health System· Source

• Not yet recruiting

  Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

  NCT07923591· Phase 2· United Therapeutics· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Akeso· Source

• Recruiting

  Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA

  NCT07828704· Phase 2· Henry Ford Health System· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Recruiting

  AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

  NCT07797335· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of LY3971297 in Participants With Heart Failure

  NCT07547540· Phase 1· Eli Lilly and Company· Source

• Recruiting

  Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents

  NCT07567833· Phase 4· Jaeb Center for Health Research· Source

• Not yet recruiting

  Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries

  NCT07418853· Henry Ford Health System· Source

• Recruiting

  Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

  NCT07646197· Henry Ford Health System· Source

• Recruiting

  Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

  NCT07599982· DreaMed Diabetes· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

  NCT07521475· Insulet Corporation· Source

• Recruiting

  UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

  NCT07054489· David Lanfear· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

  NCT07473778· Gilead Sciences· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07210723· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

  NCT07059091· Phase 2· Johns Hopkins University· Source

• Recruiting

  A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06968845· Phase 2· Rein Therapeutics· Source

• Recruiting

  Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients

  NCT06269510· Henry Ford Health System· Source

• Active, not recruiting

  A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  NCT06980480· Phase 3· Takeda· Source

• Recruiting

  A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.

  NCT07348367· Henry Ford Health System· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  NCT07294170· argenx· Source

• Recruiting

  A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System

  NCT07227532· Biosense Webster, Inc.· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  IVUS CHIP UPP Registry

  NCT06625801· ECRI bv· Source

• Recruiting

  A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07111520· Phase 1/2· BioNTech SE· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

  NCT06964464· Phase 4· University of Rochester· Source

• Recruiting

  Improving Mobility After Revascularization in Peripheral Artery Disease

  NCT06686121· Phase 3· Northwestern University· Source

• Recruiting

  RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

  NCT07002034· Phase 2· Reunion Neuroscience Inc· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· Phase 3· Celcuity Inc· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

  NCT06832618· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

  NCT06931405· Phase 2· Blueprint Medicines Corporation· Source

• Recruiting

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Active, not recruiting

  A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

  NCT06924970· Phase 2· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

  NCT06909214· Phase 4· argenx· Source

• Recruiting

  PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06673017· Phase 1· PanTher Therapeutics· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  NCT06657144· Phase 1· Coherus Oncology, Inc.· Source

Showing 50 of 174.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure10 recruiting
• Lung cancer10 recruiting
• Childhood cancers5 recruiting
• COPD5 recruiting
• ALS (motor neurone disease)4 recruiting
• Atrial fibrillation4 recruiting
• Acute myeloid leukaemia3 recruiting
• Amyloidosis3 recruiting
• Colorectal cancer3 recruiting
• Coronary artery disease3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Head and neck cancer3 recruiting
• High blood pressure3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Kidney cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Myasthenia gravis3 recruiting
• Obesity3 recruiting
• Pancreatic cancer3 recruiting
• Peripheral artery disease3 recruiting
• Prostate cancer3 recruiting
• Stroke3 recruiting
• Type 2 diabetes3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Aplastic anaemia2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Dilated cardiomyopathy2 recruiting
• Glioblastoma2 recruiting
• HIV2 recruiting
• Liver and biliary tract cancer2 recruiting
• Liver cirrhosis2 recruiting
• Multiple myeloma2 recruiting
• Osteoarthritis2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Sickle cell disease2 recruiting
• Triple-negative breast cancer2 recruiting
• Type 1 diabetes2 recruiting
• ANCA-associated vasculitis1 recruiting
• Ankylosing spondylitis1 recruiting
• Bladder cancer1 recruiting
• Brain metastases1 recruiting
• Cervical cancer1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Diabetic eye disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastroparesis1 recruiting
• Glaucoma1 recruiting
• Haemophilia1 recruiting
• Hepatitis B1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Hypothyroidism1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lupus (SLE)1 recruiting
• Meningioma1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Osteonecrosis (avascular necrosis)1 recruiting
• Ovarian cancer1 recruiting
• Parkinson disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Trigeminal neuralgia1 recruiting

Closed trials

• Completed

  Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

  NCT07240831· Biobeat Technologies Ltd.· Source

• Completed

  An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes

  NCT07276776· Insulet Corporation· Source

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Takeda· Source

• Completed

  Bright Light Therapy on Sleep Health in Lung Cancer Patients

  NCT07064395· Henry Ford Health System· Source

• Completed

  Innovative Automated Insulin Delivery System for Type 2 Diabetes

  NCT06853990· Deka Research and Development· Source

• Completed

  Prenatal Yoga to Prevent Postpartum Depression

  NCT06004232· Henry Ford Health System· Source

• Completed

  Sapphire 3 CTO Study

  NCT06358508· OrbusNeich· Source

• Completed

  A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

  NCT06299111· Phase 2· Regeneron Pharmaceuticals· Source

• Completed

  Access BNP Clinical Enrollment Study

  NCT06624293· Beckman Coulter, Inc.· Source

• Terminated

  Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

  NCT06045793· Phase 2· Tonix Pharmaceuticals, Inc.· Source

• Completed

  A Study to Evaluate Solriktug in Adult Participants With Asthma

  NCT06496607· Phase 2· Uniquity One (UNI)· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Completed

  Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes

  NCT06273124· Tandem Diabetes Care, Inc.· Source

• Withdrawn

  Mandibular Advancement Device (MAD) in Pregnant Women With Obstructive Sleep Apnea (OSA)

  NCT06256640· Henry Ford Health System· Source

• Completed

  Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial

  NCT06089135· Baim Institute for Clinical Research· Source

• Terminated

  A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

  NCT06039384· Phase 1· Incyte Corporation· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

  NCT06060665· Phase 3· Gilead Sciences· Source

• Terminated

  Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

  NCT05909995· Phase 1· Incyte Corporation· Source

• Completed

  Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

  NCT05971381· Avita Medical· Source

• Recruiting

  Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

  NCT05727176· Phase 2· Taiho Oncology, Inc.· Source

• Completed

  A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

  NCT05785832· Tandem Diabetes Care, Inc.· Source

• Completed

  Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

  NCT05775406· Phase 1· Kymera Therapeutics, Inc.· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Recruiting

  Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

  NCT05383170· Phase 1/2· Cytovation AS· Source

• Completed

  A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

  NCT05775289· Phase 2· Hoffmann-La Roche· Source

• Completed

  24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

  NCT05634746· Phase 3· Ellodi Pharmaceuticals, LP· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Completed

  Abbott i-STAT High Sensitivity Troponin I Study

  NCT05629572· Abbott Point of Care· Source

• Completed

  A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

  NCT05514535· Phase 3· Novo Nordisk A/S· Source

• Terminated

  Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

  NCT05318105· Nuwellis, Inc.· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

  NCT05143177· Phase 2/3· REDNVIA Co., Ltd.· Source

• Completed

  A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

  NCT05398445· Phase 3· Amgen· Source

• Completed

  NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

  NCT05340621· Phase 1/2· OnKure, Inc.· Source

• Terminated

  A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

  NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source

• Terminated

  Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

  NCT05251727· Phase 1· Asahi Kasei Therapeutics, Inc.· Source

• Completed

  Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

  NCT05104853· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Withdrawn

  Incorporating Supersaturated Oxygen in Shock

  NCT04876040· TherOx· Source

• Completed

  Safe Surveillance of PCI Under Mechanical Circulatory Support With the Saranas Early Bird Bleed Monitoring System

  NCT05077657· Saranas, Inc.· Source

• Terminated

  Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

  NCT05177107· Phase 2· Adaptive Phage Therapeutics, Inc.· Source

• Completed

  An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

  NCT04950764· Phase 1· Gilead Sciences· Source

• Completed

  A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

  NCT06734117· Hoffmann-La Roche· Source

• Completed

  Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

  NCT04980482· Phase 2· Arbutus Biopharma Corporation· Source

• Terminated

  KZR-261 in Subjects With Advanced Solid Malignancies

  NCT05047536· Phase 1· Kezar Life Sciences, Inc.· Source

• Completed

  realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

  NCT04981795· Incyte Corporation· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  Comparison of Type 2 Diabetes Pharmacotherapy Regimens

  NCT05073692· Kaiser Permanente· Source

• Completed

  Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

  NCT04798664· Abramson Cancer Center at Penn Medicine· Source

Showing 50 of 106.

Conditions

Diseases this institution publishes on or runs trials for.

• Deep vein thrombosis and pulmonary embolism46 works · 5 trials
• Atopic dermatitis (eczema)34 works · 5 trials
• Pancreatic cancer32 works · 10 trials
• Psoriasis32 works · 2 trials
• Glioblastoma28 works · 10 trials
• Insomnia27 works · 0 trials
• Hidradenitis suppurativa25 works · 0 trials
• Vitiligo22 works · 3 trials
• Head and neck cancer14 works · 16 trials
• Hepatitis C13 works · 0 trials
• Brain metastases13 works · 2 trials
• Neuroendocrine tumours12 works · 0 trials
• Aortic aneurysm12 works · 0 trials
• Hyperparathyroidism5 works · 0 trials
• Narcolepsy5 works · 0 trials
• Primary biliary cholangitis5 works · 5 trials
• Graves' disease4 works · 0 trials
• Essential tremor4 works · 0 trials
• Neurofibromatosis type 13 works · 0 trials
• Uterine fibroids3 works · 2 trials